COMMUNIQUÉS West-GlobeNewswire

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026
24/08/2026
DUBLIN and BRIDGEWATER, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced upcoming [...]
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease
24/08/2026
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Eisai [...]
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
24/08/2026
U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA introduces a dedicated [...]
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
24/08/2026
-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON, Aug. 24, 2026 (GLOBE [...]
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
24/08/2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, [...]
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
24/08/2026
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, [...]
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
24/08/2026
Engagement advances clinical execution of IBC101, Liminatus’ CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. ( [...]
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on [...]
ADARx Pharmaceuticals Receives FDA Fast Track Designation for Onvuzosiran for the Treatment of HAE
24/08/2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast [...]
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
24/08/2026
- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP- [...]
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
24/08/2026
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung cancers Additional [...]
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
24/08/2026
WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the [...]
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
24/08/2026
Cell-based immunotherapy program is designed to harness patients’ own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without [...]
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
24/08/2026
PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced [...]
La Commission européenne autorise TECVAYLI®▼ (teclistamab) de Johnson & Johnson associé au daratumumab dans le traitement du myélome multiple récidivant ou réfractaire, offrant ainsi une nouvelle référence thérapeutique potentielle
24/08/2026
Cette autorisation repose sur des données de Phase 3 sans précédent, démontrant une amélioration statistiquement significative de la survie sans progression et de la survie globale par rapport aux schémas thérapeutiques [...]
Kraig Biocraft Laboratories Boosts Spider Silk Output More Than 30% During the Most Technically Challenging Season of the Year
24/08/2026
Company Achieves Record Growth Through Peak Rainy Season, with Management Confirming Even Greater Output Within Reach ANN ARBOR, Mich., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
Felix Health launches sleep apnea care through new collaboration with MedSleep
24/08/2026
With more than one in four Canadian adults estimated to be at high risk for obstructive sleep apnea, Felix is expanding into sleep apnea care to help patients more easily access assessment and appropriate treatment. The [...]
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
24/08/2026
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with [...]
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
24/08/2026
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]

Pages